Tepper Jeffrey S, Kuehl Philip J, Cracknell Stuart, Nikula Kristen J, Pei Luqi, Blanchard James D
Tepper Nonclinical Consulting, San Carlos, CA, USA
Lovelace Respiratory Research Institute, Albuquerque, NM, USA.
Int J Toxicol. 2016 Jul;35(4):376-92. doi: 10.1177/1091581815624080. Epub 2016 Feb 7.
Developing inhaled drugs requires knowledge of lung anatomy, cell biology, respiratory physiology, particle physics, and some plumbing. Although dose makes the poison, in the context of an inhaled drug, the "dose" is not easily defined. This lack of clarity around dose poses issues and challenges in the design of inhalation toxicology programs. To better understand dose, the influence of ventilation is discussed as are the perturbations in pulmonary function observed with inhalation exposure that can affect dose. Methods for determining inhaled drug deposition to arrive at an estimate of lung dose are examined. Equally important to understanding dose are the techniques used to deliver aerosols to animals. With a better understanding of dose and inhalation exposure, species-specific histopathologic lesions, both common background and toxicologically significant lesions, are reviewed. Finally, insight into how regulators synthesize and evaluate these complex findings to assess clinical safety risks is presented.
开发吸入性药物需要了解肺部解剖学、细胞生物学、呼吸生理学、粒子物理学以及一些管道知识。虽然剂量决定毒性,但在吸入性药物的背景下,“剂量”并不容易定义。剂量方面的这种不明确性给吸入毒理学项目的设计带来了问题和挑战。为了更好地理解剂量,本文讨论了通气的影响以及吸入暴露时观察到的可影响剂量的肺功能扰动。研究了确定吸入药物沉积以估算肺部剂量的方法。对于理解剂量同样重要的是用于向动物递送气雾剂的技术。在更好地理解剂量和吸入暴露的基础上,本文回顾了物种特异性组织病理学病变,包括常见的背景病变和具有毒理学意义的病变。最后,介绍了监管机构如何综合和评估这些复杂的研究结果以评估临床安全风险。